Suven Life Sciences Limited — Updates, 08-01-2025: Press Release

Suven Life Sciences has initiated dosing of the first subjects in its Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator aimed at treating cognitive disorders. Conducted in the USA under FDA acceptance, this trial assesses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy individuals. Part-1 involves a single ascending dose study targeting around 40 subjects, while Part-2 will focus on multiple ascending doses with about 24 participants over 14 days. This compound is the fifth to advance in Suven's pipeline, which targets significant unmet needs in neuroscience. With patented rights across major markets, the successful development of SUVN-I6107 may bolster Suven’s position in the CNS therapeutics sector. The continued progress in clinical development could present potential growth opportunities for investors.